Concepedia

Adaptive Dose-finding

Adaptive Dose-Finding is a sequential experimental methodology in clinical trial design that iteratively adjusts dosage levels for subsequent participants based on accumulating responses, distinguishing itself by its use of real-time data adaptation to identify an optimal therapeutic dose.

171

Publications

9.7K

Citations

745

Authors

358

Institutions

Publications per year

2017–2026

38

Parents

Publications

171

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

Jeong Heo, Tony Reid, Leyo Ruo et al. · Nature Medicine · 2013 · 776 citations · Full text

, , +16

Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs

Peter F. Thall, John D. Cook · Biometrics · 2004 · 510 citations

, , +13

Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group

Paul Gallo, Christy Chuang‐Stein, Vladimir Dragalin et al. · Journal of Biopharmaceutical Statistics · 2006 · 317 citations

, , +16

Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding study

Patti Massicotte, Margaret Adams, Velma Marzinotto et al. · The Journal of Pediatrics · 1996 · 252 citations

, , +16

Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response

Mario Cazzola, Diethelm Messinger, Vittorio Battistel et al. · Blood · 1995 · 222 citations

, , +16

1–5 of 171

Authors

745

  1. YY
    Ying Yuan

    The University of Texas MD Anderson Cancer Center, United States

    16 publications · 1.2K citations

    14

    h-index

  2. PF
    Peter F. Thall

    The University of Texas MD Anderson Cancer Center, United States

    10 publications · 1.1K citations

    10

    h-index

  3. BG
    Brenda Gaydos

    Eli Lilly (United States), United States

    8 publications · 813 citations

    8

    h-index

  4. SB
    Scott Berry

    Berry & Associates (United States), United States

    8 publications · 336 citations

    8

    h-index

  5. VD
    Vladimir Dragalin

    GlaxoSmithKline (United States), United States

    8 publications · 656 citations

    8

    h-index

1–5 of 745

Institutions

358

  1. The University of Texas MD Anderson Cancer Center

    Houston, United States

    26 h-index

    83 publications

    5.4K citations

  2. Eli Lilly (United States)

    Indianapolis, United States

    9 h-index

    30 publications

    1.9K citations

  3. Pfizer (United States)

    New York, United States

    9 h-index

    17 publications

    1.3K citations

  4. Columbia University

    New York, United States

    8 h-index

    16 publications

    1.2K citations

  5. Novartis (Switzerland)

    Basel, Switzerland

    8 h-index

    17 publications

    1.1K citations

  6. Berry & Associates (United States)

    Dexter, United States

    7 h-index

    15 publications

    584 citations

  7. Inserm

    Paris, France

    6 h-index

    16 publications

    470 citations

  8. Novartis (United States)

    New York, United States

    6 h-index

    11 publications

    1.1K citations

1–8 of 358

Venues

  1. Statistics in Medicine

    21 publications · 900 citations

    19

    h-index

  2. Journal of Biopharmaceutical Statistics

    JBS · 15 publications · 957 citations

    12

    h-index

  3. Clinical Trials

    10 publications · 726 citations

    10

    h-index

  4. Biometrics

    6 publications · 700 citations

    6

    h-index

  5. Annals of Oncology

    5 publications · 179 citations

    5

    h-index

1–5